Mon, Apr 14, 1:07 PM (29 days ago)
**CNBX Pharmaceuticals Inc. (CNBX) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue reported for Q1 2025, consistent with Q1 2024. - **Profit Margins:** Operating loss of $64,743 (Q1 2025) vs. $240,845 (Q1 2024), showing a significant improvement due to reduced expenses. - **Cash Flow:** Negative cash flow from operations of $90,741 (Q1 2025) vs. $196,244 (Q1 2024). Positive cash flow from financing activities of $110,000 (Q1 2025) vs. $24,993 (Q1 2024). - **Earnings Changes:** Net loss of $69,788 (Q1 2025) vs. $325,459 (Q1 2024), indicating improved financial performance. **Quarterly Performance Discussion:** - **Expenses:** Total operating expenses decreased by $176,102 due to reduced general administration and research and development costs. - **Liquidity:** Cash increased to $45,675 (Q1 2025) from $26,416 (Q4 2024), but the company faces substantial doubt about its ability to continue as a going concern. - **Future Operations Impact:** The company plans to start Phase I/II clinical trials in 2023 and will need to raise additional capital to fund operations and repay liabilities. **Trends and Uncertainties:** - **Positive Trends:** Reduced operating expenses and improved net loss. - **Uncertainties:** Dependence on raising additional capital, regulatory developments, and market acceptance of products. - **Future Outlook:** The company's ability to continue as a going concern is uncertain, and it will need to secure additional financing to meet its obligations. **Conclusion:** CNBX Pharmaceuticals Inc. showed improved financial performance in Q1 2025 compared to Q1 2024, with reduced operating expenses and net loss. However, the company faces significant uncertainties and will need to secure additional financing to continue operations and repay liabilities. The future outlook is dependent on successful clinical trials, regulatory developments, and market acceptance of its products.